Finil Drug Interactions

Metabolism/Transport Effects Substrate of CYP2C9 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential. Inhibits CYP2C8 (weak), CYP2C9 (weak).
Avoid Concomitant Use: There are no known interactions where it is recommended to avoid concomitant use.
Increased Effect/Toxicity: Candesartan may increase the levels/effects of: ACE inhibitors; amifostine; antihypertensives; cyclosporine (systemic); Duloxetine; hypotensive agents; levodopa; lithium; non-steroidal anti-inflammatory agents; obinutuzumab; potassium-sparing diuretics; risperidone; rituximab; sodium phosphates.
The levels/effects of Candesartan may be increased by: Alfuzosin; Aliskiren; Barbiturates; Brimonidine (topical); canagliflozin; dapoxetine; diazoxide; eplerenone; heparin; heparin (low molecular weight); herbs (hypotensive properties); MAO inhibitors; nicorandil; pentoxifylline; phosphodiesterase 5 inhibitors; potassium salts; prostacyclin analogues; tolvaptan; trimethoprim.
Decreased effect: The levels/effects of candesartan may be decreased by Herbs (Hypertensive properties); methylphenidate; non-steroidal anti-inflammatory agents; yohimbine.